Antibody-targeted HPMA copolymer-bound anthracycline antibiotics

Drugs of the Future

Volumn 28, Issue 12, 2003, Pages 1189-1210

  Říhová, Blanka ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBODY; CD71 ANTIBODY; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY B.72.3; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; UNCLASSIFIED DRUG;

ADVANCED CANCER; BINDING AFFINITY; BONE MARROW TOXICITY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TARGETING; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNOGENICITY; MULTIDRUG RESISTANCE; REVIEW;

EID: 1042269568     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.12.857390     Document Type: Review

References (145)

1. Vitetta, E.S., Uhr, J.W. The potential use of immunotoxins in transplantation, cancer therapy, and immunoregulation. Transplantation 1984, 37: 535-48.
2. Vitetta, E.S., Thorpe, P.E., Uhr, J.W. Immunotoxins: Magic bullets or misquided missiles? Immunol Today 1993, 14: 252-64.
3. Št'astný, M., Ulbrich, K., Strohalm, J., Rossmann, P., Říhová, B. Abnormal differentiation of thymocytes induced by free cyclosporine is avoided when cyclosporine bound to N-(2-hydroxypropyl)methacrylamide copolymer carrier is used. Transplantation 1997, 63: 1818-27.
4. Rossmann, P., Říhová, B., Strohalm, J., Ulbrich, K. Morphology of rat kidney and thymus after native and antibody-coupled cyclosporin A application (reduced toxicity of targeted drug). Folia Microbiol 1997, 42: 277-87.
5. Jansen, F.K., Blythman, H.E., Cariére, D. et al. Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 1982, 62: 185-216.
6. Arnon, R., Sela, M. In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol Rev 1982, 62: 5-27.
7. Raso, V. Antibody mediated delivery of toxic molecules to antigen bearing target cells. Immunol Rev 1982, 62: 93-117.
8. Neville, D.M., Youle, R.J. Monoclonal antibody-ricin or ricin A chain hybrids: Kinetic analysis of cell killing for tumor therapy. Immunol Rev 1982, 62: 75-91.
9. Vitetta, E.S., Krolick, K.A., Uhr, J.W. Neoplastic B cells as targets for antibody-ricin A chain immunotoxins. Immunol Rev 1982, 62, 159-83.
10. Press, O.W., Howell-Clark, S., Anderson, I., Bernstein, I. Retention of B-cell specific monoclonal antibodies by human lymphoma cells. Blood 1994, 83: 1390-7.
11. Gottstein, C., Winkler, U., Bohlen, H., Diehl, V., Engert, A. Immunotoxins: Is there a clinical value? Ann Oncol 1994, 5: S97-S103.
12. Kopeček, J. Controlled degradability of polymers - A key to drug delivery systems. Biomaterials 1984, 5: 19-25.
13. Kopeček, J. The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery. J Control Release 1990, 11: 279-90.
14. Kopeček, J., Kopečková, P., Minko, T., Lu, Z.R. HPMA copolymer-anticancer drug conjugates: Design, activity, and mechanism of action. Eur J Pharmaceut Biopharm 2000, 50: 61-81.
15. Kopeček, J., Kopečková, P., Minko, T., Lu, Z.-R., Peterson, C.M. Water soluble polymers in tumor targeted delivery. J Control Release 2001, 74: 147-58.
16. Říhová, B., Kopeček, J. Biological properties of targetable poly[N-(2-hydroxypropyl) methacrylamide]-antibody conjugates. J Control Release 1985, 2: 289-310.
17. Říhová, B., Kopeček, J., Kopeckova-Rejmanova, P., Strohalm, J., Plocová, D., Semorádová, H. Bioaffinity therapy with antibodies and drugs bound to soluble synthetic polymers. J Chromatogr Biomed Appl 1986, 376: 221-33.
18. Říhová, B., Kopečková, P., Strohalm, J., Rossmann, P., Vetvička, V., Kopeček, J. Antibody-directed affinity therapy applied to the immune system: In vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin Immunol Immunopathol 1988, 46: 100-14.
19. Říhová, B., Krinick, N. L., Kopeček, J. Targetable photoactivatable drugs. J Mater Sci: Mater Med 1991, 2: 238-42.
20. Říhová, B., Jegorov, A., Strohalm, J., Mat'ha, V., Rossmann, P., Fornůsek, L., Ulbrich, K Antibody-targeted cyclosporin A. J Control Release 1992, 19: 25-39.
21. Říhová, B. Antibody-targeted polymer-bound drugs. Folia Microbiol 1995, 40: 367-84.
22. Říhová, B., Strohalm, J., Plocová, D. et al. Cytotoxic and cytostatic effects of anti-Thy 1.2 targeted doxorubicin and cyclosporin A. J Control Release 1996, 40: 303-19.
23. Říhová, B., Jelínková, M., Strohalm, J. et al. The anti-proliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with mouse Thy-1.2 gene. Bioconj Chem 2000, 11: 664-73.
24. 2-targeted conjugates and combined therapy with immunomodulators. J Control Release 2000, 64: 241-61.
25. Říhová, B., Strohalm, J., Kubáč ková, K. et al. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. J Control Release 2002, 78: 97-114.
26. Říhová, B. Immunomodulating activities of soluble synthetic polymer-bound drugs. Adv Drug Del Rev 2002, 54: 653-74.
27. Říhová, B., Strohalm, J., Kubáč ková, K. et al. Drug-HPMA-Hulg conjugates effective against human solid cancer. In: Polymer Drugs in the Clinical Stage. Maeda et al. (Eds.). Kluwer Academic/Plenum Publishers: New York 2003, 125-43.
28. Říhová, B., Strohalm, J., Prausová, J. et al. Cytostatic and immunomobilizing activities of polymer-bound drugs; experimental and first clinical data. J Control Release 2003, 91: 1-16.
29. Říhová, B., Kubáčková, K. Clinical implications of N-(2-hydroxypropyl)methacrylamide copolymers. Curr Pharmaceut Biotechnol 2003, 4: 311-22.
30. Flanagan, P.A., Kopečková, P., Kopeček, J., Duncan, R. Evaluation of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug carriers. 1. Binding, pinocytic uptake and intracellular distribution of transferrin and antitransferrin receptor antibody conjugates. Biochim Biophys Acta 1989, 993: 83-91.
31. Flanagan, P.A., Duncan, R., Říhová, B., Šubr, V., Kopeček, J. Immunogenicity of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates in A/J and B10 mice. J Bioact Comp Polym 1990, 5: 151-66.
32. Št'astný, M., Říhová, B., Strohalm, J., Ulbrich, K. Comparison of the binding kinetics of antibody-targeted N-(2-hydroxypropyl)methacrylamide (HPMA)-bound doxorubicin in vitro and in vivo. J Control Release 1996, 42: 229-36.
33. Št'astný, M., Strohalm, J., Plocová, D., Ulbrich, K., Říhová, B. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by an tibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. Eur J Cancer 1999, 35: 459-66.
34. 6 conjugates and a preliminary study of their photodynamic effect on mouse splenocytes in vitro. Makromol Chem 1990, 191: 839-56.
35. Omelyanenko, V., Gentry, C., Kopečková, P., Kopeček, J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Intl J Cancer 1998, 75: 600-8.
36. Omelyanenko, V., Kopečková, P., Gentry, C., Kopeček, J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release 1998, 53: 25-37.
37. Kovář, M., Strohalm, J., Ulbrich, K., Ří hová, B. In vitro and in vivo effect of HPMA copolymer-bound doxorubicin targeted to transferrin receptor of B-cell lymphoma 38C13. J Drug Targ 2002, 10: 23-30.
38. Kovář, M., Strohalm, J., Etrych, T., Ulbrich, K., Říhová, B. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: A novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect. Bioconj Chem 2002, 13: 206-15.
39. 6-OV-TL 16 antibody immunoconjugates. J Control Release 2001, 74: 249-53.
40. Duncan, R., Kopeček, J., Rejmanová, P., Lloyd, J.B. Targeting of N-(2-hydroxypro-pyl)methacrylamide copolymers to liver by incorporation of galactose residues. Biochim Biophys Acta 1983, 755: 518-21.
41. Duncan, R., Kopeček, J., Lloyd, J.B. Drug targeting to lysosomes. Biochem Soc Trans 1984, 12: 913-5.
42. Duncan, R., Seymour, L.C.W., Scarlett, L., Lloyd, J.B., Rejmanová, P., Kopeček, J. Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim Biophys Acta 1986, 880: 62-71.
43. Duncan, R., Kopeckova-Rejmanova, P., Strohalm, J. et al. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 1. Evaluation of daunomycin and puromycin conjugates in vitro. Br J Cancer 1987, 55: 165-74.
44. Duncan, R., Kopečková, P., Strohalm, J., Hume, I.C., Lloyd, J.B., Kopeček, J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br J Cancer 1988, 57: 147-56.
45. Duncan, R., Hume, I.C., Yardley, H.J., Flanagan, P.A., Ulbrich, K., Šubr, V., Strohalm, J. Macromolecular prodrugs for use in targeted cancer chemotherapy: Melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers. J Control Release 1991, 16: 121-36.
46. 6 toward human hepatocarcinoma cell fine (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy 1.2 antibodies. J Control Release 1993, 25: 71-87.
47. Seymour, L.W., Flanagan, P.A., Al-Shamkhani, A., Šubr, V., Ulbrich, K., Cassidy, J., Duncan, R. Synthetic polymers conjugated to monoclonal antibodies: Vehicles for tumour-targeted drug delivery. Select Cancer Ther 1991, 7: 59-73.
48. Rathi, R.C., Kopečková, P., Říhová, B., Kopeček, J. N-(2-Hydroxypropyl)methacrylamide copolymers containing pendant saccharide moieties. Synthesis and bioadhesive properties. J Polym Sci Part A: Polym Chem 1991, 29: 1895-902.
49. Wroblewski, S., Berenson, M., Kopečková, P., Kopeček, J. Biorecognition of HPMA copolymer-lectin conjugates as an indicator of differentiation of cell-surface glycoproteins in development, maturation and diseases of human, and rodent gastrointestinal tissues. J Biomed Mater Res 2000, 329-42.
50. Wroblewski, S., Říhová, B., Rossmann, P., Hudcovicz, T., Řeháková, Z., Kopečková, P., Kopeček, J. The influence of a colonic microbiota on HPMA copolymer-lectin conjugates binding in rodent intestine. J Drug Targ 2001, 9: 85-94.
51. O'Hare, K.B., Duncan, R., Strohalm, J., Ulbrich, K., Kopeč ková, P. Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: In vitro and in vivo evaluation against murine melanoma. J Drug Targ 1993, 1: 217-29.
52. Omelyanenko, V., Kopečková, P., Prakash, R., Ebert, Ch. D., Kopeček, J. Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes. Pharm Res 1999, 16: 1010-9.
53. Kopeček, J., Rejmanová, P., Strohalm, J. et al. Synthetic polymeric drugs. US 5037883.
54. Rejmanová, P., Kopeček, J., Duncan, R., Lloyd, J.B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers. Biomaterials 1985, 6: 45-8.
55. Duncan, R., Cable, H.C., Lloyd, J.B., Rejmanová, P., Kopeček, J. Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci Rep 1982, 2: 1041-6.
56. Encyclopedia of Immunology, 2nd Ed. Delves, P.J. and Roitt, I.M. (Eds.). Academic Press 1998.
57. Říhová, B., Ulbrich, K., Kopeček, J., Mančal, P. Immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers - Potential hapten or drug carriers. Folia Microbiol 1983, 28: 217-27.
58. Říhová, B., Kopeček, J., Ulbrich, K., Pospíšil, J., Mančal, P. Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice. Biomaterials 1984, 5: 143-8.
59. Říhová, B., Kopeček, J., Ulbrich, K., Chytrý, V. Immunogenicity of N-(2-hydroxypropyl) methacrylamide copolymers. Makromol Chem Suppl 1985, 9: 13-24.
60. Šimečková, J., Říhová, B., Plocová, D., Kopeček, J. The activity of complement in the presence of N-(2-hydroxypropyl)methacrylamide copolymers. J Bioact Comp Polym 1986, 1: 20-31.
61. Volfová, I., Říhová, B., Vétvič ka, V., Rossmann, P., Ulbrich, K. Biocompatibility of biopolymers. J Bioact Comp Polym 1992, 7: 175-90.
62. Šubr, V., Etrych, T., Ulbrich, K. et al. Synthesis and properties of poly[N-(2-hydropxypropyl)methacrylamide] conjugates of superoxide dismutase. J Bioact Comp Polym 2002, 17: 105-22.
63. Oupický, D., Ulbrich, K., Říhová, B. Conjugates of semitelechelic poly[N-(2-hydroxypropyl)methacrylamide] with enzymes for protein delivery. J Bioact Comp Polym 1999, 14: 213-31.
64. Abuchowski, A., McCoy, J.R., Palczuk, N.C., Van Es, T., Davis, F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977, 252: 3582-6.
65. Matsumura, Y., Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanisms of tumoritropic accumulation of proteins and the antitumor agent. Cancer Res 1986, 6: 6387-92.
66. Maeda, H., Matsumura, Y. Tumoritropic and lymphotropic principles of macromolecular drugs. CRC Crit Rev Ther Drug Carrier Syst 1992, 9: 135-87.
67. Maeda, H., Seymour, L.W., Miyamoto, Y. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconj Chem 1992, 3: 351-5.
68. Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., Maeda, H. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998, 89: 307-14.
69. Ulbrich, K., Zacharieva, E.I., Kopeček, J., Hume, I.C., Duncan, R. Polymer-bound derivatives of sarcolysin and their antitumour activity against mouse and human leukemia in vitro. Makromol Chem 1987, 188: 2497-509.
70. Minko, T., Kopečková, P., Kopeček, J. Efficacy of chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Intl J Cancer 2000, 86: 108-17.
71. Cassidy, J., Duncan, R., Morrison, G.J., Strohalm, J., Plocová, D., Kopeček, J., Kaye, S.B. Activity of N-(2-hydroxypropyl) methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem Pharmacol 1989, 38: 875-9.
72. 6 and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J Control Release 1999, 61: 145-57.
73. Vasey, P.A., Kaye, S.B., Morrison, R. et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 1999, 5: 83-94.
74. Říhová, B. Receptor-mediated targeted drug or toxin delivery. Adv Drug Del Rev 1998, 29: 273-89.
75. Říhová, B., Strohalm, J., Plocová, D., Ulbrich, K. Selectivity of antibody-targeted anthracycline antibiotics on T lymphocytes. J Bioact Comp Polym 1990, 5: 249-66.
76. Kovář, M., Mrkvan, T., Strohalm, J., Etrych, T., Ulbrich, K., Št'astný, M., Říhová, B. HPMA copolymer-bound doxorubicin targeted to tumor specific antigen of BCL1 mouse B cell leukemia. J Control Release 2003, 29: 315-30.
77. Jelínková, M., Strohalm, J., Etrych, T., Ulbrich, K., Říhová, B. Starlike versus classical macromolecular prodrugs: Two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs. Pharm Res 2003, 20: 1558-64.
78. Press, O.W., Vitetta, E., Farr, A., Hansen, J., Martin, P. Evaluation of ricin A chain immunotoxins directed against human T cells. Cell Immunol 1986, 102: 10-20.
79. Thorpe, P.E., Blakey, D.C., Brown, A.N. et al. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: Antitumor effects, in vivo fate, and tumor cell mutants. J Natl Cancer Inst 1987, 79: 1101-12.
80. Press, O.W., Martin, J.P., Thorpe, P.E., Vitetta, E.S. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. J Immunol 1988, 141: 4410-7.
81. Manetti, C. Le Doussal, J.M., Rouvier, E., Gruaz-Guyon, A., Barbet, J. Intracellular uptake and catabolism of anti-IgM antibodies and bispecific antibody-targeted hapten by B-lymphoma cells. Intl J Cancer 1995, 63: 250-6.
82. Matthay, K.K., Abai, A.M., Cobb, S., Hong, K., Papahadjopoulos, D., Straubinger, R.M. Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells. Cancer Res 1989, 49, 4879-86.
83. Ali, S.A., Waren, S.D., Richter, K.Y. et al. Improving the tumor retention of radioiodinated antibody: Aryl carbohydrate aducts. Cancer Res 1990, 50: 783s-8s.
84. Jelínková, M., Strohalm, J., Plocová, D., Šubr, V., Št'astný, M., Ulbrich, K., Ří hová, B. Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens. J Control Release 1998, 52: 253-70.
85. 125I]daunomycin. J Control Release 1989, 10: 37-49.
86. Duncan, R. Drug-polymer conjugates: Potential for improved chemotherapy. Anticancer Drugs 1992, 3: 175-210.
87. Říhová, B., Větvička, V., Strohalm, J., Ulbrich, K., Kopeček, J. Action of polymeric prodrugs based on N-(2-hydroxypropyl)methacrylamide copolymers. I. Suppression of the antibody response and proliferation of mouse splenocytes in vivo. J Control Release 1989, 9: 21-32.
88. Duke-Cohan, J.S., Morimoto, Ch., Schlossman, S.F. Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26. Blood 1993, 82: 2224-34.
89. 2b monoclonal antibodies. Eur J Immunol 1990, 20: 107-12.
90. Rejmanová, P., Kopeček, J., Pohl, J., Baudyš, M., Kostka, V. Polymers containing enzymatically degradable bonds, 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers by bovine spleen cathepsin B. Makromol Chem 1983, 184: 2009-20.
91. Flanagan, P.A., Duncan, R., Šubr, V., Ulbrich, K., Kopečková, P., Kopeček, J. Evaluation of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug-carriers. 2. Body distribution of conjugates containing transferrin, antitransferrin receptor antibody or anti-Thy 1.2 antibody and effectiveness of transferrin-containing daunomycin conjugates against mouse L1210 leukaemia in vivo. J Control Release 1992, 18: 25-38.
92. Ulbrich, K., Strohalm, J., Šubr, V., Plocová, D., Duncan, R., Říhová, B. Polymeric conjugates of drugs and antibodies for site-specific drug delivery. Makromol Symp 1996, 103: 177-92.
93. Hovorka, O., Št'astný, M., Etrych, T., Šubr, V., Strohalm, J., Ulbrich, K., Říhová, B. Differences in the intracellular fate of free and polymer-bound doxorubicin. J Control Release 2002, 80: 101-17.
94. Etrych, T., Jelínková, M., Říhová, B., Ulbrich, K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: Synthesis and preliminary in vitro and in vivo biological properties. J Control Release 2001, 73: 89-102.
95. Říhová, B., Etrych, T., Pechar, M. et al. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes. J Control Release 2001, 74: 225-32.
96. Ulbrich, K., Etrych, T., Chytil, P., Jelínková, M., Říhová, B. HPMA copolymers with pH-controlled release of doxorubicin in vitro cytotoxicity and in vivo antitumor activity. J Control Release 2003, 87: 33-47.
97. Omelyanenko, V., Kopečková, P., Gentry, C., Shiah, J.-G., Kopeček, J. HPMA copolymer - anticancer drug - OV-TL16 antibody conjugates. 1. Influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J Drug Target 1996, 3: 357-73.
98. Ulbrich, K., Pechar, M., Strohalm, J., Šubr, V., Říhová, B. Polymeric carriers of drugs for site-specific therapy. Makromol Symp 1997, 118: 577-85.
99. Ulbrich, K., Šubr, V., Strohalm, J., Plocová, D., Jelínková, M., Říhová, B. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterization. J Control Release 2000, 64: 63-79.
100. Lu, Z.-R., Kopečková, P., Kopeček, J. Polymerizable Fab' antibody fragments for targeting of anticancer drugs. Nature Biotechnol 1999, 17: 1101-4.
101. Waldor, M.K., Sriram, S., McDevitt, H.O., Steinman, L. In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. Proc Natl Acad Sci USA 1983, 80: 2713-7.
102. Tarnowski, G.S., Ralph, P., Stock, C.Ch. Sensitivity to chemotherapeutic and immunomodulating agents of two mouse lymphomas and of a macrophage tumor. Cancer Res 1979, 39: 3964-7.
103. Otsuji, E., Yamaguchi, T., Tsuruta, H. et al. Applicability of monoclonal antibody Fab fragments as a carrier of neocarzinostatin in targeting chemotherapy. J Surg Oncol 1996, 61: 149-54.
104. Lang, L., Jagoda, E., Wu, C. et al. Factors influencing the in vivo pharmacokinetics of peptides and antibody fragments: The pharmacokinetics of two PET-labeled low molecular weight proteins. Q J Nucl Med 1997, 41: 53-61.
105. Waldmann, T.A. Monoclonal antibodies in diagnosis and therapy. Science 1991, 252: 1657-62.
106. 2. Cancer 1996, 78: 157-68.
107. Martell, L.A., Agrawal, A., Ross, D.A., Muraszko, K.M. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 1993, 53: 1348-53.
108. Jiang, A., Chu, T.H., Nocken, F., Cichutek, K., Dornburg, R. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies. J Virol 1998, 72: 10148-56.
109. Denis, O., Macedo Soares, F., Latinne, D., Nisol, F., Bazin, H. In vivo study of mIgM and mIgD cross-linking on murine B cells. Scand J Immunol 1994, 39: 625-32.
110. Van Niekerk, C.C., Rameakers, F.C.S., Hanselaar, A.G.J.M., Aldeweireldt, J., Poels, L.G. Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am J Pathol 1993, 142: 157-77.
111. Boerman, O., Massuger, L., Makkink, K., Thomas, C., Kenemans, P., Poels, L. Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies. Anticancer Res 1990, 10: 1289-96.
112. Putnam, D., Kopeček, J. Polymer conjugates with anticancer activity. Adv Polym Sci 1995, 122: 55-123.
113. Timour, Q., Nony, P., Lang, J., Lakhal, M., Trillet, V., Faucon, G. Doxorubicin concentration time course in the myocardium after single administration to the dog. Cancer Chemother 1987, 20: 267-9.
114. Rossi C., Gasparini, G., Canobbio, L. et al. Doxorubicin distribution in human breast cancer. Cancer Treat Rep 1987, 71: 1221-6.
115. Brenner, D.E., Wiernik, P.H., Wesley, M., Bachur, N.R. Acute doxorubicin toxicity. Relationship to pretreatment, liver function, response and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer 1984, 53: 1042-8.
116. Terasaki, T., Iga, T., Sugiyama, Y., Hanano, M. Pharmacokinetic study of the mechanism of tissue distribution of doxorubicin. Inter-organ and inter-species variation in tissue to plasma partition coefficients in rats, rabbits and guinea pigs. J Pharm Sci 1984, 73: 1359-62.
117. Seymour, L.W., Duncan, R., Strohalm, J., Kopeček, J. Effect of molecular weight (MW) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J Biomed Mater Res 1987, 21: 1341-58.
118. Duncan, R., Cable, H.C., Rejmanová, P., Kopeček, J., Lloyd, J.B. Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers. Biochim Biophys Acta 1984, 799: 1-8.
119. De Duve, C., De Barsy, T., Poole, B. et al. Lysosomotropic agents. Biochem Pharmacol 1974, 23: 2495-531.
120. Hertler, A.A., Frankel, A.E. Immunotoxins: A clinical review of their use in the treatment of malignancies. J Clin Oncol 1989, 7: 1932-42.
121. Říhová, B., Bilej, M., Větvička, V., Ulbrich, K., Strohalm, J., Kopeček, J., Duncan, R. Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Biomaterials 1989, 10: 335-42.
122. Yeung, T.K., Hopewell, J.W., Simmonds, R.H. et al. Reduced cardiotoxicyty of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide cojugates: An experimental study in the rat. Cancer Chemother Pharmacol 1991, 29: 105-11.
123. Hopewell, J.W., Duncan, R., Wilding, D., Chakrabarti, K. Preclinical evaluation of the cardiotoxicity of PK2: A novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent. Hum Exp Toxicol 2001, 20: 461-70.
124. Říhová, B., Strohalm, J., Hoste, K. et al. Immunoprotective therapy with targeted anticancer drugs. Makromol Symp 2001, 172: 21-8.
125. Paluska, E., Hrubá, A., Šterba, O., Kopeček, J. Effect of a synthetic poly-N-(2-hydroxypropyl)methacrylamide (DUXON) on haemopoiesis and graft-versus-host reaction. Folia Biol 1986, 32: 91-102.
126. Endicott, J.A., Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989, 58: 137-71.
127. Gottesman, M.M. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993, 53: 747-54.
128. Pinedo, H.M., Giaccone, G. P-glycoprotein-a marker of cancer-cell behavior. New Engl J Med 1995, 333: 1417-9.
129. Minko, T., Kopečková, P., Kopeček, J. Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell fine. J Control Release 1999, 59: 133-48.
130. Suzuki, H., Zelphati, O., Hildebrand, G., Leserman, L. CD4 and CD7 molecules are targets for drug delivery from antibody bearing liposomes. Exp Cell Res 1991, 193: 112-9.
131. Van Oosterhout, Y.V., van den Herik-Oudijk, I.E., Wessels, H.M., de Witte, T., van de Winkel, J.G., Preijers, F.W. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. Cancer Res 1994, 54: 3527-32.
132. Venne, A., Li, S., Mandeville, R., Kabanov, A., Alakhov, V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport and subcellular distribution of doxorubicin in multi-drug resistant cells. Cancer Res 1996, 56: 3626-9.
133. Alakhov, V.Y., Moskaleva, E.U., Batrakova, E.V. Kabanov, A. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconj Chem 1996, 7: 209-16.
134. Dallas, G. et al. Drug transporters in the central nervous system: Brain barriers and brain parenchyma consideration. Pharmacol Rev 2001, 53: 569-96.
135. Hunter, A.Ch., Moghimi, S.M. Therapeutic synthetic polymers: A game of Russian roulette? DDT 2002, 7: 998-1001.
136. Luo, W., Tapolsky, M., Earley, K., Wood, C.G., Wilson, D.R., Logothetis, C.J., Lin, S.H. Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Ther 1999, 6: 313-21.
137. Asea, A., Kraeft., S.K., Kurt-Jones, E.A. et al. HSP70 stimulates cytokine production through a CD 14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nature Med 2000, 6: 435-42.
138. Srivastava, P.K., Menoret, A., Basu, S., Binder, R.J., McQuade, K.L. Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. Immunity 1998, 8: 657-65.
139. Srivastava, P.K., Udono, H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol 1994, 6: 728-32.
140. Demoy, M., Minko, T., Kopečková, P., Kopeček, J. Time- and concentration-dependent apoptosis and necrosis induced by free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J Control Release 2000, 69: 185-96.
141. O'Connell, J., Bennett, M.W., O'Sullivan, G.C., Collins, J.K., Shanahan, F. The Fas counterattack: Cancer as a site of immune privilege. Immunol Today 1999, 20: 46-52.
142. Friesen, C., Herr, I., Krammer, P.H., Debatin, K.M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 1996, 2: 574-7.
143. Friesen, C., Fulda, S., Debatin, K.M. Cytotoxic drugs and the CD95 pathway. Leukemia 1999, 13: 1854-8.
144. Shoenfeld, Y., Fishman, P. Gamma-globulin inhibits tumor spread in mice. Intl Immunol 1999, 11: 1247-52.
145. Thomson, A.H., Vasey, P.A., Murray, L.S., Cassidy, J., Fraier D., Frigerio, E., Twelves, C. Population pharmacokinetics in phase I drug development: A phase I study of PK1 in patients with solid tumours. Br J Cancer 1999, 81: 99-107.